Clinical Trial
doi: 10.1097/00002826-199704000-00008.Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study
Affiliations
- PMID:9099469
- DOI: 10.1097/00002826-199704000-00008
Item in Clipboard
Clinical Trial
Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study
M Merello et al. Clin Neuropharmacol.1997 Apr.
Display options
Format
Display options
Format
Abstract
Twelve parkinsonian patients with severely fluctuating symptoms were given a single dose of apomorphine or Dispersible Madopar on 2 consecutive days, to confirm the latter drug's usefulness in "off" period rescue. According to our results, apomorphine proved faster in reverting "off" periods and should still be regarded as the drug of choice for this treatment modality.
Similar articles
- Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.Deleu D, Hanssens Y, Northway MG.Deleu D, et al.Drugs Aging. 2004;21(11):687-709. doi: 10.2165/00002512-200421110-00001.Drugs Aging. 2004.PMID:15323576Review.
- Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.Limousin P, Pollak P, Pfefen JP, Tournier-Gervason CL, Dubuis R, Perret JE.Limousin P, et al.Clin Neuropharmacol. 1995 Jun;18(3):258-65. doi: 10.1097/00002826-199506000-00006.Clin Neuropharmacol. 1995.PMID:8635184Clinical Trial.
- A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.Chen JJ, Obering C.Chen JJ, et al.Clin Ther. 2005 Nov;27(11):1710-24. doi: 10.1016/j.clinthera.2005.11.016.Clin Ther. 2005.PMID:16368444Review.
- [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].Dessibourg CA, Gachoud JP.Dessibourg CA, et al.Praxis (Bern 1994). 1995 Oct 24;84(43):1235-8.Praxis (Bern 1994). 1995.PMID:7481341German.
- An add-on study of selegiline to Madopar in the treatment of parkinsonian patients with dose-related fluctuations: comparison between Jumexal and Parkryl.Shan DE, Yeh SI.Shan DE, et al.Zhonghua Yi Xue Za Zhi (Taipei). 1996 Oct;58(4):264-8.Zhonghua Yi Xue Za Zhi (Taipei). 1996.PMID:8994331Clinical Trial.
Cited by
- Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.Deleu D, Hanssens Y, Northway MG.Deleu D, et al.Drugs Aging. 2004;21(11):687-709. doi: 10.2165/00002512-200421110-00001.Drugs Aging. 2004.PMID:15323576Review.
- Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.Nyholm D.Nyholm D.Clin Pharmacokinet. 2006;45(2):109-36. doi: 10.2165/00003088-200645020-00001.Clin Pharmacokinet. 2006.PMID:16485914Review.
- Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.van Laar T.van Laar T.CNS Drugs. 2003;17(7):475-89. doi: 10.2165/00023210-200317070-00002.CNS Drugs. 2003.PMID:12751918Review.
- An update on advanced therapies for Parkinson's disease: From gene therapy to neuromodulation.Serva SN, Bernstein J, Thompson JA, Kern DS, Ojemann SG.Serva SN, et al.Front Surg. 2022 Sep 23;9:863921. doi: 10.3389/fsurg.2022.863921. eCollection 2022.Front Surg. 2022.PMID:36211256Free PMC article.Review.
- Medical Management and Prevention of Motor Complications in Parkinson's Disease.Aradi SD, Hauser RA.Aradi SD, et al.Neurotherapeutics. 2020 Oct;17(4):1339-1365. doi: 10.1007/s13311-020-00889-4.Neurotherapeutics. 2020.PMID:32761324Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical